Oxford BioDynamics targets ‘clear and rapid progress’ as revenues inch up
Oxford BioDynamics, which provides clinical tests based on its EpiSwitch genomics technology, has posted results for the year ended 30 September 2024.
Revenues have risen slightly to £0.6 million, though operating losses are also up 26 per cent at £12.9 million.
The firm welcomed a new executive chairman, Iain Ross, this January, and earlier this month hosted a visit from former PM Rishi Sunak at its Oxford HQ.
It also inked a distribution agreement with Regina Maria, Romania’s largest private healthcare provider.
Iain said: “Notwithstanding the developments and challenges this business has faced over the past year, I believe our world-class clinical tests and pipeline assets remain potentially very valuable.
“With the support of shareholders, our immediate focus is on seeking further meaningful partnerships and collaborations with diagnostic and pharmaceutical companies and increasing direct sales as a route to achieving sustainable commercial success.
“We’re well aware we need to demonstrate clear and rapid progress in order to deliver a substantial increase in shareholder value.”
